Estradiol sulfamate

Last updated
Estradiol sulfamate
Estradiol sulfamate.svg
Clinical data
Other namesE2MATE; Estradiol-3-O-sulfamate; (E2-SO2-(NH2); J995; ES-J995; PGL-2; PGL-2001; ZK-190628; BLE-00084; 17β-Hydroxyestra-1,3,5(10)-trien-3-yl sulfamate
Routes of
administration 		By mouth
Drug class Steroid sulfatase inhibitor
Pharmacokinetic data
Elimination half-life 18 days [1]
Identifiers
  • [(8R,9S,13S,14S,17S)-17-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C18H25NO4S
Molar mass 351.46 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OS(=O)(=O)N
  • InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,17+,18+/m1/s1
  • Key:YXYXCSOJKUAPJI-ZBRFXRBCSA-N

Estradiol sulfamate (E2MATE; developmental code names J995, PGL-2, PGL-2001, ZK-190628, others), or estradiol-3-O-sulfamate, is a steroid sulfatase (STS) inhibitor which is under development for the treatment of endometriosis. [2] [3] [4] [5] It is the C3 sulfamate ester of estradiol, and was originally thought to be a prodrug of estradiol. [3] [4]

Contents

Discovery

The drug was first synthesized as an STS inhibitor along with its oxidized version estrone 3-O-sulfamate (EMATE) in the group of Professor Barry V L Potter at the University of Bath, UK, working together with Professor Michael J Reed at Imperial College, London and was found to be highly estrogenic in rodents. Such aryl sulfamate esters were shown to be "first-in-class" highly potent active site-directed irreversible STS inhibitors. [6] Compounds of this class are thought to irreversibly modify the active site formylglycine residue of STS. [7]

Metabolism

The drug shows reduced susceptibility to first-pass metabolism relative to estradiol, and was believed to be the first "potent" estradiol prodrug to be discovered. [3] [4] [8]

Unlike estradiol and other estradiol esters, due to its unique sulfamate ester, E2MATE is not hydrolyzed during the first pass with oral administration, and instead can only be cleaved into estradiol systemically. [3] [4] E2MATE itself shows no affinity for the estrogen receptor or estrogenic activity in vitro , requiring hydrolysis into estradiol for estrogenicity. [3] [4] In accordance, the systemic potency of oral E2MATE as an estrogen in rodents was found to be increased approximately 100-fold relative to that of oral estradiol, whereas its hepatotropic activity is increased only marginally, by about 2- to 3-fold. [3] [9] As such, E2MATE has virtually absent effects on estrogen-modulated liver functions with oral administration at typical dosages equivalent to those of estradiol and behaves much like parenterally or transdermally administered estradiol, thereby combining the advantages of transdermal estradiol with the convenience of oral administration. [3] It has been determined that this is due to binding of E2MATE to carbonic anhydrase II in erythrocytes (red blood cells), which results in E2MATE being rapidly taken up into erythrocytes from the blood of the hepatic portal vein and bypassing the liver during the first pass with oral administration. [8] [10] Following this, E2MATE is slowly released from erythrocytes into the circulation. [8] [10] The X-ray crystal structure of EMATE in complex with carbonic anhydrase II has been determined. [11]

However, it has been found that E2MATE, without being hydrolyzed first, can be converted by 17β-hydroxysteroid dehydrogenase into estrone sulfamate (EMATE), analogously to the conversion of estradiol into estrone. [8] Moreover, EMATE is the dominant fraction found in the circulation, and EMATE is a potent STS inhibitor. [8] [12] As a result, EMATE prevents the bioactivation of itself and E2MATE into estrone and estradiol, respectively, which effectively abolishes their estrogenic activity in humans. [8] [13] In relation to these findings, according to Elger and colleagues, "In spite of high levels of [E2MATE] and EMATE in the circulation, only insignificant [estradiol] levels and no estrogenic effects were generated in humans. [...] Further, EMATE is a potent inhibitor of the STS. It is obvious from estrogenicity studies that this property impairs the release of estrone and [estradiol] in a species varied manner. STS inhibition in the human was probably the mechanism for very long lasting high [E2MATE]- and EMATE concentrations in erythrocytes compared to shorter initial peak values of [estrone] and [estradiol] in the plasma." [8] As such, E2MATE and EMATE are not effective as estrogens in humans, and the researchers have subsequently developed new C17β sulfonamide ester prodrugs of estradiol, such as EC508, that cannot be transformed into the corresponding estrone equivalents and are not STS inhibitors. [8]

STS is an enzyme that is responsible for the transformation of hormonally inactive steroid sulfates into their hormonally active forms, for instance hydrolysis of estrone sulfate into estrone (which can then be transformed into the more potent estradiol). [4] Inhibition of STS is the basis for the clinical development of E2MATE for endometriosis, as STS is expressed in the endometrium, and the severity of endometriosis has been found to correlate with STS expression. [4] In a clinical study, E2MATE was found to inhibit endometrial STS activity by 91% in premenopausal women, while circulating levels of estradiol were not affected, indicating that E2MATE may have tissue-selective antiestrogenic effects in the endometrium. [4]

E2MATE is rapidly and 90% transformed into EMATE in the intestines during the first pass with oral administration in women. [1] EMATE and E2MATE are almost completely sequestered into erythrocytes from the hepatic portal vein during the first pass with oral administration, thereby bypassing the liver. [1] Treatment with 4 mg oral E2MATE once per week has been found to result in very high maximal levels of E2MATE of 152.1 ng/mL (152,100 pg/mL) and of EMATE of 2,395 ng/mL (2,395,000 pg/mL) in women. [1] Maximal levels of E2MATE and EMATE occur about 3.5 to 5.5 days after a dose of E2MATE. [1] There is a 4.0-fold accumulation of E2MATE and a 3.3-fold accumulation of EMATE with continuous administration of E2MATE relative to a single dose. [1] The biological half-life of E2MATE with continuous administration has been found to be about 18 days and of EMATE about 16 days in women. [1]

Research

It was clinically investigated for possible use as an estrogen for indications like hormonal contraception and menopausal hormone therapy. [4] [8] However, it showed no estrogenic effects in women. [4] [8] The potent non-estrogenic clinical STS inhibitor Irosustat (STX64/667-Coumate) was used to explore the possibility that STS might be responsible for the hydrolysis of estrogen sulphamates. Results demonstrated convincingly that STS is the enzyme responsible for the removal of the sulfamoyl group from estrogen sulfamates and has a crucial role in regulating the estrogenicity associated with this class of drug. [14] Thus, STS inhibition blocks the conversion of E2MATE into estradiol and thereby abolishes its estrogenicity in humans. [8] Irosustat has completed a number of clinical trials in oncology as an STS inhibitor currently up to Phase II. [7]

STS inhibition was also found to be a potential new therapy for endometriosis. [13] Following this, E2MATE was repurposed as an STS inhibitor for the treatment of estrogen-dependent conditions like endometriosis. [4] [2] As of 2017, E2MATE is in phase II clinical trials for endometriosis. [2] [ needs update ]


See also

Related Research Articles

<span class="mw-page-title-main">2-Methoxyestradiol</span> Chemical compound

2-Methoxyestradiol is a natural metabolite of estradiol and 2-hydroxyestradiol (2-OHE2). It is specifically the 2-methyl ether of 2-hydroxyestradiol. 2-Methoxyestradiol prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis), hence it is an angiogenesis inhibitor. It also acts as a vasodilator and induces apoptosis in some cancer cell lines. 2-Methoxyestradiol is derived from estradiol, although it interacts poorly with the estrogen receptors. However, it retains activity as a high-affinity agonist of the G protein-coupled estrogen receptor (GPER).

<span class="mw-page-title-main">Steroid sulfatase</span> Protein-coding gene in the species Homo sapiens

Steroid sulfatase (STS), or steryl-sulfatase, formerly known as arylsulfatase C, is a sulfatase enzyme involved in the metabolism of steroids. It is encoded by the STS gene.

<span class="mw-page-title-main">Estrone sulfate</span> Chemical compound

Estrone sulfate, also known as E1S, E1SO4 and estrone 3-sulfate, is a natural, endogenous steroid and an estrogen ester and conjugate.

A steroidogenesis inhibitor, also known as a steroid biosynthesis inhibitor, is a type of drug which inhibits one or more of the enzymes that are involved in the process of steroidogenesis, the biosynthesis of endogenous steroids and steroid hormones. They may inhibit the production of cholesterol and other sterols, sex steroids such as androgens, estrogens, and progestogens, corticosteroids such as glucocorticoids and mineralocorticoids, and neurosteroids. They are used in the treatment of a variety of medical conditions that depend on endogenous steroids.

<span class="mw-page-title-main">Ethinylestradiol sulfonate</span> Estrogenic drug

Ethinylestradiol sulfonate (EES), sold under the brand names Deposiston and Turisteron among others, is an estrogen medication which has been used in birth control pills for women and in the treatment of prostate cancer in men. It has also been investigated in the treatment of breast cancer in women. The medication was combined with norethisterone acetate in birth control pills. EES is taken by mouth once per week.

<span class="mw-page-title-main">Steroid ester</span> Class of chemical compounds

A steroid ester is an ester of a steroid. They include androgen esters, estrogen esters, progestogen esters, and corticosteroid esters. Steroid esters may be naturally occurring/endogenous like DHEA sulfate or synthetic like estradiol valerate. Esterification is useful because it is often able to render the parent steroid into a prodrug of itself with altered chemical properties such as improved metabolic stability, water solubility, and/or lipophilicity. This, in turn, can enhance pharmacokinetics, for instance by improving the steroid's bioavailability and/or conferring depot activity and hence an extended duration with intramuscular or subcutaneous injection.

<span class="mw-page-title-main">Estradiol sulfate</span> Chemical compound

Estradiol sulfate (E2S), or 17β-estradiol 3-sulfate, is a natural, endogenous steroid and an estrogen ester. E2S itself is biologically inactive, but it can be converted by steroid sulfatase into estradiol, which is a potent estrogen. Simultaneously, estrogen sulfotransferases convert estradiol to E2S, resulting in an equilibrium between the two steroids in various tissues. Estrone and E2S are the two immediate metabolic sources of estradiol. E2S can also be metabolized into estrone sulfate (E1S), which in turn can be converted into estrone and estradiol. Circulating concentrations of E2S are much lower than those of E1S. High concentrations of E2S are present in breast tissue, and E2S has been implicated in the biology of breast cancer via serving as an active reservoir of estradiol.

<span class="mw-page-title-main">Irosustat</span> Chemical compound

Irosustat is an orally active, irreversible, nonsteroidal inhibitor of steroid sulfatase (STS) and member of the aryl sulfamate ester class of drugs that was under development by Sterix Ltd and Ipsen for the treatment of hormone-sensitive cancers such as breast cancer, prostate cancer, and endometrial cancer but has not yet been marketed. The drug was first designed and synthesized in the group of Professor Barry V L Potter at the Department of Pharmacy & Pharmacology, University of Bath, working together with Professor Michael J. Reed at Imperial College, London and its initial development was undertaken through the university spin-out company Sterix Ltd and overseen by Cancer Research UK (CRUK). Results of the "first-in-class" clinical trial in breast cancer of an STS inhibitor in humans were published in 2006 and dose optimisation studies and further clinical data have been reported.

<span class="mw-page-title-main">Estrone sulfamate</span> Chemical compound

Estrone sulfamate, or estrone-3-O-sulfamate, is a steroid sulfatase (STS) inhibitor which has not yet been marketed. It is the C3 sulfamate ester of the estrogen estrone. Unlike other estrogen esters however, EMATE is not an effective prodrug of estrogens. A closely related compound is estradiol sulfamate (E2MATE), which is extensively metabolized into EMATE and has similar properties to it.

<span class="mw-page-title-main">Estrone (medication)</span> Estrogen medication

Estrone (E1), sold under the brand names Estragyn, Kestrin, and Theelin among many others, is an estrogen medication and naturally occurring steroid hormone which has been used in menopausal hormone therapy and for other indications. It has been provided as an aqueous suspension or oil solution given by injection into muscle and as a vaginal cream applied inside of the vagina. It can also be taken by mouth as estradiol/estrone/estriol and in the form of prodrugs like estropipate and conjugated estrogens.

<span class="mw-page-title-main">Estrone sulfate (medication)</span> Chemical compound

Estrone sulfate (E1S) is an estrogen medication and naturally occurring steroid hormone. It is used in menopausal hormone therapy among other indications. As the sodium salt, it is the major estrogen component of conjugated estrogens (Premarin) and esterified estrogens. In addition, E1S is used on its own as the piperazine salt estropipate. The compound also occurs as a major and important metabolite of estradiol and estrone. E1S is most commonly taken by mouth, but in the form of Premarin can also be taken by parenteral routes such as transdermal, vaginal, and injection.

<span class="mw-page-title-main">EC508</span> Chemical compound

EC508, also known as estradiol 17β-(1- -L-proline), is an estrogen which is under development by Evestra for use in menopausal hormone therapy and as a hormonal contraceptive for the prevention of pregnancy in women. It is an orally active estrogen ester – specifically, a C17β sulfonamide–proline ester of the natural and bioidentical estrogen estradiol – and acts as a prodrug of estradiol in the body. However, unlike oral estradiol and conventional oral estradiol esters such as estradiol valerate, EC508 undergoes little or no first-pass metabolism, has high oral bioavailability, and does not have disproportionate estrogenic effects in the liver. As such, it has a variety of desirable advantages over oral estradiol, similarly to parenteral estradiol, but with the convenience of oral administration. EC508 is a candidate with the potential to replace not only oral estradiol in clinical practice, but also ethinylestradiol in oral contraceptives. Evestra intends to seek Investigational New Drug status for EC508 in the second quarter of 2018.

<span class="mw-page-title-main">Estriol sulfamate</span> Chemical compound

Estriol sulfamate, or estriol 3-O-sulfamate, is a synthetic estrogen and estrogen ester which was never marketed. It is the C3 sulfamate ester of estriol. The drug shows substantially improved oral estrogenic potency relative to estriol in rats but without an increase in hepatic estrogenic potency. However, the closely related compound estradiol sulfamate (E2MATE) failed to show estrogenic activity in humans, which is due to the fact that it is additionally a highly potent inhibitor of steroid sulfatase which regulates the estrogenicity of such compounds and thus it prevents its own bioactivation into estradiol.

<span class="mw-page-title-main">Ethinylestradiol sulfamate</span> Chemical compound

Ethinylestradiol sulfamate, or 17α-ethynylestradiol 3-O-sulfamate, is a synthetic estrogen and estrogen ester which was never marketed. It is the C3 sulfamate ester of ethinylestradiol. The drug shows considerably improved oral estrogenic potency (uterotrophic) relative to ethinylestradiol in rats but without an increase in hepatic estrogenic potency. Related compounds like ethinylestradiol N,N-diethylsulfamate (J271) and ethinylestradiol pyrrolidinosulfonate (J272) have also been developed, and have similar properties in animals. However, the closely related compound estradiol sulfamate (E2MATE) failed to show estrogenic activity in humans, which is due to the fact that it is additionally a highly potent inhibitor of steroid sulfatase and prevents its own bioactivation into estradiol.

<span class="mw-page-title-main">Pharmacokinetics of estradiol</span>

The pharmacology of estradiol, an estrogen medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.

<span class="mw-page-title-main">Barry V. L. Potter</span> British biochemist

Barry Victor Lloyd Potter MAE FMedSci is a British chemist, who is Professor of Medicinal & Biological Chemistry at the University of Oxford, Wellcome Trust Senior Investigator and a Fellow of University College, Oxford.

<span class="mw-page-title-main">Estrone phosphate</span> Chemical compound

Estrone phosphate (E1P), or estrone 3-phosphate, is an estrogen and steroid sulfatase inhibitor which was never marketed. It has similar affinity for steroid sulfatase as estrone sulfate and acts as a competitive inhibitor of the enzyme. In contrast to estrone sulfate however, it is not hydrolyzed by steroid sulfatase and is instead metabolized by phosphatases.

<span class="mw-page-title-main">2-Methoxyestradiol disulfamate</span> Chemical compound

2-Methoxyestradiol disulfamate is a synthetic, oral active anti-cancer medication which was previously under development for potential clinical use. It has improved potency, low metabolism, and good pharmacokinetic properties relative to 2-methoxyestradiol (2-MeO-E2). It is also a potent inhibitor of steroid sulfatase, the enzyme that catalyzes the desulfation of steroids such as estrone sulfate and dehydroepiandrosterone sulfate (DHEA-S).

References

  1. 1 2 3 4 5 6 7 Pohl O, Bestel E, Gotteland JP (October 2014). "Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age". Reproductive Sciences. 21 (10): 1256–1265. doi:10.1177/1933719114522526. PMID   24604234. S2CID   206805308.
  2. 1 2 3 "PGL 2". AdisInsight. Springer Nature Switzerland AG.
  3. 1 2 3 4 5 6 7 Elger W, Barth A, Hedden A, Reddersen G, Ritter P, Schneider B, et al. (2001). "Estrogen sulfamates: a new approach to oral estrogen therapy". Reproduction, Fertility, and Development. 13 (4): 297–305. doi:10.1071/RD01029. PMID   11800168.
  4. 1 2 3 4 5 6 7 8 9 10 11 Thomas MP, Potter BV (September 2015). "Estrogen O-sulfamates and their analogues: Clinical steroid sulfatase inhibitors with broad potential". The Journal of Steroid Biochemistry and Molecular Biology. 153: 160–169. doi:10.1016/j.jsbmb.2015.03.012. PMID   25843211. S2CID   24116740.
  5. ↑ Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B (December 1995). "Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application". The Journal of Steroid Biochemistry and Molecular Biology. 55 (3–4): 395–403. doi:10.1016/0960-0760(95)00214-6. PMID   8541236. S2CID   31312.
  6. ↑ Thomas MP, Potter BV (October 2015). "Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health". Journal of Medicinal Chemistry. 58 (19): 7634–7658. doi:10.1021/acs.jmedchem.5b00386. PMC   5159624 . PMID   25992880.
  7. 1 2 Potter BV (August 2018). "SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects". Journal of Molecular Endocrinology. 61 (2): T233–T252. doi: 10.1530/JME-18-0045 . PMID   29618488.
  8. 1 2 3 4 5 6 7 8 9 10 11 Elger W, Wyrwa R, Ahmed G, Meece F, Nair HB, Santhamma B, et al. (January 2017). "Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions". The Journal of Steroid Biochemistry and Molecular Biology. 165 (Pt B): 305–311. doi:10.1016/j.jsbmb.2016.07.008. PMID   27449818. S2CID   26650319.
  9. ↑ Elger W, Palme HJ, Schwarz S (April 1998). "Novel oestrogen sulfamates: a new approach to oral hormone therapy". Expert Opinion on Investigational Drugs. 7 (4): 575–589. doi:10.1517/13543784.7.4.575. PMID   15991994.
  10. 1 2 Ahmed G, Elger W, Meece F, Nair HB, Schneider B, Wyrwa R, Nickisch K (October 2017). "A prodrug design for improved oral absorption and reduced hepatic interaction". Bioorganic & Medicinal Chemistry. 25 (20): 5569–5575. doi:10.1016/j.bmc.2017.08.027. PMID   28886996.
  11. ↑ Abbate F, Winum JY, Potter BV, Casini A, Montero JL, Scozzafava A, Supuran CT (January 2004). "Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase". Bioorganic & Medicinal Chemistry Letters. 14 (1): 231–234. doi:10.1016/j.bmcl.2003.09.064. PMID   14684333.
  12. ↑ Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 233–239. ISBN   978-3-642-60107-1.
  13. 1 2 Purohit A, Fusi L, Brosens J, Woo LW, Potter BV, Reed MJ (February 2008). "Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy". Human Reproduction. 23 (2): 290–297. doi: 10.1093/humrep/dem308 . PMID   18056119.
  14. ↑ Chander SK, Purohit A, Woo LW, Potter BV, Reed MJ (September 2004). "The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates". Biochemical and Biophysical Research Communications. 322 (1): 217–222. doi:10.1016/j.bbrc.2004.07.108. PMID   15313194.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.